220 related articles for article (PubMed ID: 11934811)
1. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment.
de Beer EL; Bottone AE; van Der Velden J; Voest EE
Mol Pharmacol; 2000 Jun; 57(6):1152-7. PubMed ID: 10825385
[TBL] [Abstract][Full Text] [Related]
3. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment.
Bottone AE; Voest EE; de Beer EL
Clin Cancer Res; 1998 Apr; 4(4):1031-7. PubMed ID: 9563899
[TBL] [Abstract][Full Text] [Related]
4. Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain.
Hydock DS; Wonders KY; Schneider CM; Hayward R
Anticancer Res; 2009 Nov; 29(11):4401-7. PubMed ID: 20032385
[TBL] [Abstract][Full Text] [Related]
5. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.
Hydock DS; Lien CY; Schneider CM; Hayward R
Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619
[TBL] [Abstract][Full Text] [Related]
6. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
7. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Imondi AR
Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
[TBL] [Abstract][Full Text] [Related]
8. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
[TBL] [Abstract][Full Text] [Related]
9. Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Mwale F; Ciobanu I; Demers CN; Antoniou J; Héon S; Servant N; Chalifour LE
Calcif Tissue Int; 2005 Sep; 77(3):175-9. PubMed ID: 16151678
[TBL] [Abstract][Full Text] [Related]
10. Persistent effects of doxorubicin on cardiac gene expression.
Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA
J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
12. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
13. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system.
Bottone AE; de Beer EL; Voest EE
J Mol Cell Cardiol; 1997 Mar; 29(3):1001-8. PubMed ID: 9152861
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
19. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]